Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Abou-Alfa, Ghassan K.Meyer, TimCheng, Ann-LiiEl-Khoueiry, Anthony B.Rimassa, LorenzaRyoo, Baek-YeolCicin, Irfan2024-06-122024-06-1220180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.4_suppl.207https://hdl.handle.net/20.500.14551/25936Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CA[Abstract Not Available]en10.1200/JCO.2018.36.4_suppl.207info:eu-repo/semantics/closedAccess[No Keywords]Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.Conference Object364Q1WOS:000436174100199